Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights
GlobeNewswire • Nov 16, 2026
Read articleAcrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB
GlobeNewswire • Nov 6, 2026
Read articleAcrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
GlobeNewswire • Nov 4, 2026
Read articleAcrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
GlobeNewswire • Oct 29, 2026
Read articleAcrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027
GlobeNewswire • Oct 20, 2026
Read articleWhat Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock
Zacks • Sep 15, 2026
Read article